Is There an Added Value of Quantitative DCE-MRI by Magnetic Resonance Dispersion Imaging for Prostate Cancer Diagnosis?
Auke JagerJorg R OddensArnoud W PostemaRazvan L MicleaIvo G SchootsPeet G T A NooijenHans van der LindenJelle O BarentszStijn W T P J HeijminkHessel WijkstraMassimo MischiSimona TurcoPublished in: Cancers (2024)
In this multicenter, retrospective study, we evaluated the added value of magnetic resonance dispersion imaging (MRDI) to standard multiparametric MRI (mpMRI) for PCa detection. The study included 76 patients, including 51 with clinically significant prostate cancer (csPCa), who underwent radical prostatectomy and had an mpMRI including dynamic contrast-enhanced MRI. Two radiologists performed three separate randomized scorings based on mpMRI, MRDI and mpMRI+MRDI. Radical prostatectomy histopathology was used as the reference standard. Imaging and histopathology were both scored according to the Prostate Imaging-Reporting and Data System V2.0 sector map. Sensitivity and specificity for PCa detection were evaluated for mpMRI, MRDI and mpMRI+MRDI. Inter- and intra-observer variability for both radiologists was evaluated using Cohen's Kappa. On a per-patient level, sensitivity for csPCa for radiologist 1 (R1) for mpMRI, MRDI and mpMRI+MRDI was 0.94, 0.82 and 0.94, respectively. For the second radiologist (R2), these were 0.78, 0.94 and 0.96. R1 detected 4% additional csPCa cases using MRDI compared to mpMRI, and R2 detected 20% extra csPCa cases using MRDI. Inter-observer agreement was significant only for MRDI (Cohen's Kappa = 0.4250, p = 0.004). The results of this study show the potential of MRDI to improve inter-observer variability and the detection of csPCa.
Keyphrases
- prostate cancer
- radical prostatectomy
- magnetic resonance
- contrast enhanced
- high resolution
- magnetic resonance imaging
- end stage renal disease
- nuclear factor
- artificial intelligence
- computed tomography
- newly diagnosed
- chronic kidney disease
- double blind
- randomized controlled trial
- emergency department
- label free
- clinical trial
- risk assessment
- electronic health record
- adverse drug
- immune response
- sensitive detection
- placebo controlled
- quantum dots
- study protocol
- deep learning
- drug induced